CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo
Data presented at 2021 American Epilepsy Society Meeting provide proof of concept for CODA-engineered ligand-gated ion channels
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- CODA Biotherapeutics ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo. Collectively, the results showed efficacy of the CODA chemogenetic approach in controlling spontaneous seizures in a model system that replicates many features of human temporal lobe epilepsy.
The study was conducted by a team of neuroscientists led by Ivan Soltesz, PhD, the James R. Doty Professor of Neurosurgery and Neurosciences at the Stanford University School of Medicine. The data were presented in a poster presentation entitled, "Controlling focal seizures using novel chemogenetic tools," at the American Epilepsy Society (AES) 2021 Annual Meeting, held December 3-5, 2021 in Chicago, IL. (Abstract 1.406). The poster abstract can be found on the AES website here.
"These data provide in vivo proof of concept for the treatment of focal epilepsy with CODA's chemogenetic technology," said Michael Narachi, president and CEO of CODA "We look forward to advancing the overall platform toward the clinic, led by these exciting results, which provide new hope for patients suffering with intractable focal epilepsies."
In addition to Dr. Soltesz, study co-authors included Peter M. Klein, PhD (presenting author), Quynh Anh Nguyen, PhD, and Jesslyn Homidan.
About the CODA Platform
About Focal Epilepsy and Neuropathic Pain
According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain – an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.
About CODA Biotherapeutics
View original content to download multimedia:https://www.prnewswire.com/news-releases/coda-biotherapeutics-chemogenetic-gene-therapy-platform-can-control-focal-seizures-in-vivo-301438518.html
SOURCE CODA Biotherapeutics, Inc.